Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors. Read more on ...
Keep the news in the Wayback Machine. Sign Fight for the Future's letter. Please Don't Scroll Past This Can you chip in? The Internet Archive partners with libraries, archives, and institutions across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results